By Gabrielle Masson – Fierce Biotech –
Bayer’s Parkinson’s disease cell therapy is moving into late-stage testing, with the upcoming trial set to be the first registrational phase 3 study for an investigational allogeneic cell therapy in the neurodegenerative disease.
Bemdaneprocel will be studied in a sham-surgery controlled, double-blind trial that is expected to start in the first half of this year, Bayer’s BlueRock Therapeutics outfit announced Jan. 13 in tandem with the annual J.P. Morgan Healthcare Conference.
